Opus Genetics, Inc. (IRD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Annual

0 5M 10M 15M FY24: 11M FY25: 14.2M FY24 FY25

Gross Profit Annual

-105K -70K -35K 0 35K 70K 105K FY09: -100K FY09

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-75M -50M -25M 0 25M 50M 75M FY24: -62.1M FY25: -38.6M FY24 FY25

Net Income Annual

-60M -40M -20M 0 20M 40M 60M FY24: -57.5M FY25: -49.6M FY24 FY25

Cost of Revenue Annual

0 35K 70K 105K FY09: 100K FY09

Operating Cash Flow Annual

-45M -30M -15M 0 15M 30M 45M FY24: -25.6M FY25: -35.3M FY24 FY25

Free Cash Flow Annual

-7.5M -5M -2.5M 0 2.5M 5M 7.5M FY19: -3.6M FY20: -6.8M FY19 FY20

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 25M 50M 75M FY24: 26.7M FY25: 62.2M FY24 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.40 -1.60 -0.80 0.00 0.80 1.60 2.40 Q3 '24: -1.07 Q4 '24: -2.15 Q1 '25: -2.10 Q2 '25: -1.92 Q3 '25: -1.88 Q4 '25: -0.82 Q1 '26: -1.33 Q2 '26: -1.35 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25 Q1 '26 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.